StamlerJ., StamlerR., RiedlingerW.F., AlgeraG., RobertsR.H.Hypertension screening of 1 million Americans. Community Hypertension Evaluation Clinic (CHEC) program, 1973 through 1975. Jama, 1976; 235(21):2299–2306.
2.
KannelW.B., McGeeD.L.Diabetes and cardiovascular risk factors: the Framingham study. Circulation, 1979; 59(1):8–13.
3.
The Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation, 1979; 60(2): 427-39.
4.
MakhsidaN., ShahJ., YanG., FischH., ShabsighR.Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol, 2005; 174(3):827–834.
5.
NettleshipJ.E., JonesT.H., ChannerK.S., JonesR.D.Testosterone replacement therapy attenuates fatty streak formation and improves high density lipoprotein cholesterol in the Tfm mouse; an effect which is independent of the classical nuclear androgen receptor. Circulation, 2007; 116:2427–2434.
6.
MullerM., van den BeldA.W., van der SchouwY.T., GrobeeD.E., LambertsS.W.Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation, 2004; 109(17):2074–2079.
7.
MakinenJ., JarvisaloM.J., PollanenP., PereentupaA., IrjalaK., KoskenvuoM., et al.Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol, 2005; 45(10):1603–1608.
8.
HakA.E., WittemanJ.C., de JongF.H., GeerlingsM.I., HofmanA., PolsH.A.Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab, 2002; 87(8):3632–3639.
9.
EnglishK.M., MandourO., SteedsR.P., JonesT.H., ChannerK.S.Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J, 2000; 21(11):890–894.
10.
ShoresM.M., MatsumotoA.M., SloanK.L., KivlahanD.R.Low serum testosterone and mortality in male veterans. Arch Intern Med, 2006; 166(15):1660–1665.
11.
AraujoA., KupelianV., PageS.T., HandelsmanD.J., BremnerW.J., McKinlayJ.B.Sex steroids and all-cause mortality and cause-specific mortality in men. Arch Intern Med, 2007; 167:1252–1260.
12.
MalkinC.J., JonesR.D., JonesT.H., ChannerK.S.Effect of testosterone on ex vivo vascular reactivity in man. Clin Sci (Lond), 2006; 111(4):265–274.
13.
HammL.Testosterone propionate in the treatment of angina pectoris. J Clin Endocrinol, 1942; 2:325–328.
14.
WalkerT.C.The use of testosterone propionate and estrogenic substance in the treatment of essential hypertension, angina pectoris and peripheral vascular disease. Journal of Clinical Endocrinology, 1942; 2:560–568.
15.
SiglerL.H.T.J.Treatment of angina pectoris by testosterone propionate. New York State Journal of Medicine, 1943; 43:1424–1428.
16.
LesserM.A.Testosterone propionate therapy in one hundred cases of angina pectoris. Journal of Clinical Endocrinology, 1946; 6:549–557.
17.
JaffeM.D.Effect of testosterone cypionate on postexercise ST segment depression. Br Heart J, 1977; 39(11):1217–1222.
18.
WuS.Z., WengX.Z.Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chin Med J (Engl), 1993; 106(6):415–418.
19.
WebbC.M., McNeillJ.G., HaywardC.S., de ZeiglerD., CollinsP.Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation, 1999; 100(16):1690–1696.
20.
EnglishK.M., SteedsR.P., DiverM.J., JonesT.H., ChannerK.S.Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation, 2000; 102(16):1906–1911.
21.
RosanoG.M., LeonardoF., PagnottaP., PellicciaF., PaninaG., CerquetaniE., et al.Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation, 1999; 99(13):1666–1670.
22.
ThompsonP.D., AhlbergA.W., MoynaN.M., DuncanB., Ferraro-BorgidaM., WhiteC.M., et al.Effect of intravenous testosterone on myocardial ischemia in men with coronary artery disease. Am Heart J, 2002; 143(2):249–256.
23.
MalkinC.J., PughP.J., MorrisP.D., HallJ., JonesR.D., JonesT.H., et al.Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart, 2004; 90(8):871–876.
24.
PughP.J., JonesT.H., ChannerK.S.Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J, 2003; 24(10):909–915.
25.
PughP.J., JonesR.D., WestJ.N., JonesT.H., ChannerK.S.Testosterone treatment for men with chronic heart failure. Heart, 2004; 90(4):446–447.
26.
MalkinC.J., PughP.J., WestJ.N., van BeekE.J.R., JonesT.H., ChannerK.S.Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J, 2006; 27(1):57–64.
27.
JankowskaE.A., BielB., MajdaJ., SzklarskaA., LopuszanskaM., MedrasM., et al.Anabolic deficiency in men with chronic heart failure; prevalence and detrimental impact on survival. Circulation, 2006; 114:1829–1837.
28.
MalkinC.J., PughP.J., JonesR.D., KapoorD., ChannerK.S., JonesT.H.The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab, 2004; 89(7):3313–3318.
